Clin2
NCT06493370Possibly a fitRecruiting

IV vitamin C plus chemo for bladder cancer

Bladder Cancer

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests adding high-dose vitamin C (ascorbate) to a standard chemotherapy combination for people with muscle-invasive bladder cancer who cannot take or choose not to take cisplatin. The goal is to find a more affordable and effective treatment option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
48 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old.
  • You have muscle-invasive bladder cancer and cannot take cisplatin (or have chosen not to).
  • You are able to be up and about (ECOG performance status 0-2).
  • Your blood counts and kidney/liver function are within acceptable ranges.
  • You are not currently using tobacco or willing to stop for 2 weeks before starting.
  • You do not have a history of G6PD deficiency or oxalate kidney stones.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06364904Not yet recruiting· Phase 3
Immunotherapy plus chemo for advanced bladder cancer

This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.

Guangzhou, Guangdong
NCT06571708Recruiting· Phase 2
Chemo plus immunotherapy for muscle-invasive bladder cancer

This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.

New York, New York
NCT06957561Not yet recruiting· Phase 1/Phase 2
Study of Disitamab Vedotin and Ivonescimab for bladder cancer

This trial tests a combination of two drugs for people with muscle-invasive bladder cancer who cannot receive cisplatin chemotherapy. The drugs target cancer cells and may help the body's immune system fight the tumor.

Guangzhou, Guangdong
NCT06963346Recruiting· Phase 1
Bladder cancer trial: targeted drug plus immunotherapy before surgery

This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.

Tampa, Florida
NCT07121036Recruiting· Phase 1
High-dose vitamin C infusion for advanced solid tumors

This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.

Wuhan, Hubei
NCT03418038Recruiting· Phase 2
Vitamin C with chemotherapy for certain relapsed blood cancers

This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.

Mankato, Minnesota

Hear when a new Bladder Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.